ENDOCYP2D6: Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes

• Sponsor: Jules Desmeules (Other)
• Overall Status: Completed
• CT.gov ID: NCT04188028
• Collaborator: (none)
• Enrollment: 40
• Location: 1
• Arms: 2
• Actual Duration (Months): 12
• Patients Per Site Per Month: 3.3

Study Details

Study Description

Brief Summary

CYP2D6 metabolizes ~25% of all marketed drugs. There is an important variability in the activity of this enzyme among individuals. The cause of this variability might be environmental, genetic, ethnical or even related to a disease. The administration of a CYP2D6 probe drug (e.g. dextromethorphan) is a good way to characterize CYP2D6 phenotype. Nonetheless, it is relatively invasive and the vulnerable population (e.g. pregnant women) cannot be phenotyped in this manner. Therefore, finding an endogenous substance which is metabolized by CYP2D6 could replace usual phenotyping procedure using a probe drug. This study evaluates the impact of a CYP2D6 inhibitor and of genetic polymorphism on the metabolome of healthy volunteers in order to identify new CYP2D6 biomarkers. To this end, untargeted metabolomics analysis using LC-HRMS will be performed on plasma and urine samples This single-centre open-label clinical trial will include 40 healthy subjects (men and women) between 18 and 65 years. Eligible participants will be assigned to a study group according to their CYP2D6 genotypes: poor metabolizers (PMs) and extensive/ultrarapid metabolizers (EMs-UMs). Two sessions will take place for each subjects.

Session 1: CYP2D6 phenotyping (dextromethorphan 5 mg, single dose) Session 2: idem session 1 with prior uptake of a CYP2D6 inhibitor (paroxetine 10 or 20 mg, one dose a day for 7 days).

In both sessions, urine will be collected up to 24 hours and capillary/venous blood will be sampled before phenotyping for metabolomics analyses. Urine will also be collected for 4 hours after dextromethorphan intake in order to phenotype the CYP2D6 enzyme.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: Dextromethorphan 5 MG; Drug: Paroxetine 10Mg Tablet; Drug: Paroxetine 20Mg Tablet	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 40 participants
• Allocation: Non-Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes: Use of Metabolomics for the Identification of New CYP2D6 Endogenous Biomarkers in Healthy Volunteers
• Actual Study Start Date: Jan 1, 2019
• Actual Primary Completion Date: Jul 31, 2019
• Actual Study Completion Date: Dec 31, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: CYP2D6 gene score 0 CYP2D6 gene score 0: carrier of two non-functional alleles	Drug: Dextromethorphan 5 MG; dextromethorphan 5 mg po; Drug: Paroxetine 10Mg Tablet; Paroxetine 10 mg po
Experimental: CYP2D6 gene score ≥1 CYP2D6 gene score ≥1: carrier of one fully-functional and one non-functional allele of CYP2D6 , one fully-functional and one reduced-function of CYP2D6, two fully-functional alleles of CYP2D6 or more than two functional alleles alleles	Drug: Dextromethorphan 5 MG; dextromethorphan 5 mg po; Drug: Paroxetine 20Mg Tablet; Paroxetine 20 mg po

Outcome Measures

Primary Outcome Measures

1. Identify endogenous markers of CYP2D6 activity in urine and plasma using untargeted metabolomics [7 days]

   Metabolomic strategie (LC-Q-Exactive HRMS) will be used to identify and characterize endogenous compounds that correlate with the urinary metabolic ratio dextromethorphan/dextrorphan before and after administration of paroxetine, a strong CYP2D6 inhibitor.

Secondary Outcome Measures

1. Difference in DEM/DOR urinary ratio before and after administration of paroxetine [7 days]

2. Correlation of significant ions with DEM/DOR urinary ratio or CYP2D6 activity score [7 days]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Healthy men and women

• Age 18-65 years

• Body Mass Index (BMI) 18-27

• Understanding of French language and able to give a written inform consent

• CYP2D6 genotype : activity score = 0 (PMs) or activity score ≥ 1 (EMs-UMs)

• Reliable contraception during the whole study, including a barrier method

Exclusion Criteria:

• Participation in any other interventional clinical study within 3 months prior to inclusion

• Pregnant or breastfeeding woman

• Any pathologies, use of drugs or food that may affect CYP activity (based on the 'drug interactions and cytochromes P450' table published by the Service of Clinical Pharmacology and Toxicology, HUG54 and on the investigator's knowledge)

• Regular smokers of ≥ 10 cigarettes/day

• Alcohol intake 2 days prior to session 1 and during paroxetine intake

• Medical history of chronic alcoholism or abuse of psychoactive drugs

• Regular use of psychotropic substances

• Sensitivity to any of the drugs used

• Alteration of hepatic tests (ASAT, ALAT, BILI, GGT) more than 3x normal

• Psychiatric disorders

• Beck Score ≥10 (question related to suicide >0)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	HUG	Geneva		Switzerland

Sponsors and Collaborators

• Jules Desmeules

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Jules Desmeules, Professor, University Hospital, Geneva
• ClinicalTrials.gov Identifier: NCT04188028
• Other Study ID Numbers: 2018-01637
• First Posted: Dec 5, 2019
• Last Update Posted: Jan 4, 2022
• Last Verified: Jan 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Dextromethorphan; Paroxetine

Study Results

No Results Posted as of Jan 4, 2022